Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell, Marginal Zone 2Waldenstrom Macroglobulinemia 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 27Rituximab 26fludarabine phosphate 18Filgrastim 17fludarabine 13Lenalidomide 13Peripheral Blood Stem Cell Transplantation 12Bortezomib 12Bendamustine Hydrochloride 12ibrutinib 9venetoclax 8Etoposide 8Paclitaxel 7Flow Cytometry 7Cyclosporine 7tanespimycin 6aldesleukin 6Prednisone 6Magnetic Resonance Spectroscopy 6Cytarabine 6Biopsy 6obinutuzumab 5Vorinostat 5Tacrolimus 5Radiotherapy 5Polymerase Chain Reaction 5Melphalan 5Gemcitabine 5sargramostim 4belinostat 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, B-Cell, Marginal Zone × pirtobrutinib × Clear all
NCT05024045 2026-03-03

Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

Eli Lilly and Company

Phase 1 Active not recruiting
316 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hematologic Diseases, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05990465 2026-02-23

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Medical College of Wisconsin

Phase 1 Recruiting
12 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡